Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines

医学 心肌梗塞 指南 血管紧张素受体阻滞剂 内科学 随机对照试验 心力衰竭 临床试验 盐皮质激素受体 队列 心脏病学 药方 重症监护医学 血管紧张素转换酶 醛固酮 药理学 血压 病理
作者
Caterina Mas‐Llado,Xavier Rosselló,Maribel González‐Del‐Hoyo,Stuart Pocock,Frans Van de Werf,Chee Tang Chin,Nicolas Danchin,Stephen W-L Lee,Jesús Medina,Yong Huo,Héctor Bueno
出处
期刊:The American Journal of Medicine [Elsevier]
卷期号:137 (2): 137-146.e10 被引量:3
标识
DOI:10.1016/j.amjmed.2023.09.021
摘要

Objective We aimed to evaluate the applicability of the eligibility criteria of randomized controlled trials (RCTs) cited in guideline recommendations in a real-world cohort of patients receiving secondary prevention after acute myocardial infarction from the EPICOR registries. Methods Recommendations provided by American and European guidelines for acute myocardial infarction were classified into general (applying to all patients) and specific (applying to patients with left ventricular dysfunction or heart failure). Randomized controlled trials cited in these recommendations were selected, and their entry criteria were applied to our international cohort of 18,117 patients. Results There were 91.5% patients eligible for beta blockers (84.6% for general, and 5.9% for specific recommendations), 97.7% eligible for renin-angiotensin system inhibitor (angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers [ACEI/ARB]) recommendations (69.9% for general, 27.9% for specific) and 4.1% eligible for mineralocorticoid receptor antagonists (only specific recommendations). The percentages of patients with eligibility criteria who were discharged with a prescription of the recommended therapies were 80%-85% for beta blockers, 70%-75% for ACEI/ARB, and 29% for mineralocorticoid receptor antagonists. There were large regional variations in the percentage of eligible patients and in those receiving the medications (eg, 95% in Northern Europe and 57% in Southeast Asia for beta blockers). Conclusion Most real-world acute myocardial infarction patients are eligible for secondary prevention therapy in both general and specific guideline recommendations, and the percentage of those on beta blockers and ACEI/ARB at hospital discharge is high. There are large regional variations in the proportion of patients receiving recommended therapies. Local targeted interventions are needed for quality improvement.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
半夏完成签到,获得积分10
1秒前
zorro完成签到,获得积分10
1秒前
yyyy完成签到,获得积分20
1秒前
adgfasdvz完成签到 ,获得积分10
2秒前
枣子完成签到,获得积分10
3秒前
梦在远方完成签到 ,获得积分10
3秒前
张张完成签到 ,获得积分10
4秒前
逸风望完成签到,获得积分10
4秒前
小小li完成签到 ,获得积分10
5秒前
苻人英完成签到,获得积分10
5秒前
冬至完成签到 ,获得积分10
7秒前
shimfey完成签到 ,获得积分10
7秒前
虚拟的尔蓝完成签到 ,获得积分10
8秒前
jjjjchou完成签到,获得积分10
9秒前
CodeCraft应助乐乐采纳,获得10
9秒前
qiuhx1053完成签到 ,获得积分10
10秒前
容与完成签到 ,获得积分0
10秒前
jiayue完成签到,获得积分10
10秒前
温眼张完成签到,获得积分10
11秒前
11秒前
Yang22完成签到,获得积分10
11秒前
与月同行完成签到,获得积分10
12秒前
SXYYY完成签到,获得积分10
12秒前
12秒前
我超爱cs完成签到,获得积分10
13秒前
yiqichihuoguoa完成签到 ,获得积分10
14秒前
FJ完成签到,获得积分10
15秒前
小破网完成签到 ,获得积分0
15秒前
妖怪大大完成签到,获得积分10
15秒前
OnionJJ完成签到,获得积分10
15秒前
好好学习完成签到 ,获得积分10
15秒前
良辰完成签到,获得积分10
15秒前
南南发布了新的文献求助10
16秒前
2026毕业啦完成签到,获得积分10
16秒前
16秒前
16秒前
高级后勤完成签到,获得积分10
16秒前
清浅溪完成签到 ,获得积分10
17秒前
小羊完成签到,获得积分10
18秒前
you完成签到,获得积分10
19秒前
高分求助中
Lire en communiste 1000
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 800
Becoming: An Introduction to Jung's Concept of Individuation 600
Communist propaganda: a fact book, 1957-1958 500
Briefe aus Shanghai 1946‒1952 (Dokumente eines Kulturschocks) 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3167282
求助须知:如何正确求助?哪些是违规求助? 2818793
关于积分的说明 7922334
捐赠科研通 2478522
什么是DOI,文献DOI怎么找? 1320396
科研通“疑难数据库(出版商)”最低求助积分说明 632776
版权声明 602443